Simon Lab at the FHCRC
List of FDA-Approved Non-biological Anticancer Drugs
These data have not been endorsed by the National Cancer Institute or the Fred Hutchinson Cancer Research Center.
This is a listing of all chemical agents approved for the treatment of cancer. The compounds have been divided into the traditional categories according to mechanism of action or structural similarities. The highlighted drugs have been tested in the Field Station's Yeast Screen. These results can be viewed by following the link.
Lomustine (NSC-79037)
Carmustine (NSC-409962)
Streptozocin (NSC-85998)
Mechlorethamine (NSC-762)
Melphalan (NSC-8806)
Uracil Nitrogen Mustard (NSC-34462)
Chlorambucil (NSC-3088)
Cyclophosphamide (NSC-26271)
Iphosphamide (NSC-109724)
Cisplatin (NSC-119875)
Carboplatin (NSC-2412240)
Mitomycin (NSC-26980)
Thiotepa (NSC-6396)
Dacarbazin (NSC-45388)
Procarbazine (NSC-77213)
Hexamethyl Melamine (NSC-13875)
Triethylene Melamine (NSC-9706)
Busulfan (NSC-750)
Pipobroman (NSC-25154)
Mitotane (NSC-38721)
Methotrexate (NSC-740)
Trimetrexate (NSC-249008), a Methotrexate analog
Pentostatin (NSC-218321)
Cytarabine (NSC-63878)
Ara-CMP (NSC-99445), an activated form of Cytarabine
Fludarabine phosphate (NSC-312887)
Hydroxyurea (NSC-32065)
Fluorouracil (NSC-19893)
Floxuridine (NSC-27640)
Chlorodeoxyadenosine (NSC-105014)
Gemcitabine (NSC-613327)
Thioguanine (NSC-752)
6-Mercaptopurine (NSC-755)
Bleomycin (NSC-125066)
Topotecan (NSC-609699)
Irinotecan (NSC-616348)
Camptothecin sodium salt (NSC-100880), a strucutral analog of Topotecan and Irinotecan
Daunorubicin (NSC-82151)
Doxorubicin (NSC-123127)
Idarubicin (NSC-256439)
Mitoxantrone (NSC-301739)
Teniposide (NSC-122819)
Etoposide (NSC-141540)
Dactinomycin (NSC-3053)
Mithramycin (NSC-24599)
Vinblastine (NSC-49842)
Vincristine (NSC-67574)
Navelbine (NSC-608210)
Paclitaxel (NSC-125973)
Docetaxel (NSC-628503)
Some brief thoughts on the generally accepted mechanism of action for the FDA-approved drugs.
Return to the Yeast Screen Main Page.
Return to the
Simon Lab Home Page.
Send comments and questions to Julian Simon.